Rheumatoid ArthritisPhase 2DARWIN3NCT02065700
Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Participants
A Phase 2 study testing Filgotinib in people with Rheumatoid Arthritis, run by Lakefront Biotherapeutics NV at 111 sites in 22 countries.
Trial summary
The primary objective of the study was to evaluate the long-term safety and tolerability of filgotinib (formerly GLPG0634) for the treatment of rheumatoid arthritis. Participants were enrolled in this open-label long-term follow-up study after they had completed one of the two core studies, GLPG0634-CL-203 (DARWIN1)… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Rheumatoid Arthritis
- What is being tested?
- Filgotinib
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 739 participants
- Where
- 111 sitesin 22 countries
- Study dates
- 25 Feb 2014to 19 Jan 2023
- Phase
- Phase 2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participants who completed one of the qualifying core studies GLPG0634-CL-203 or GLPG0634-CL-204 and may benefit from filgotinib long-term treatment according to the Investigator's judgment
- Females of childbearing potential and sexually active men must agree to use highly effective method of birth control as specified in the protocol, during the study and for at least 12 weeks after the last dose of filgotinib
Who cannot join
- Participants who prematurely withdrew from one of the 2 core studies (GLPG0634-CL-203 or GLPG0634-CL-204), for any reason
- Persistent abnormal lab values during one of the 2 core studies (GLPG0634-CL-203 or GLPG0634-CL-204), according to the Investigator's judgment
- Diagnosis of rheumatic autoimmune disease or inflammatory joint disease other than rheumatoid arthritis, except for secondary Sjogren's syndrome
- Any condition or circumstances which, in the opinion of the Investigator, may make a participant unlikely or unable to complete the study or comply with study procedures and requirements
- Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Trial locations and contacts
111 sites in 22 countries.
111 sites in 22 countries
United States15 sites
Austin Rheumatology Research PA
Austin, Texas
RASF Clinical Research Center
Boca Raton, Florida
Low County Rheumatology PA
Charleston, South Carolina
Arthro, Arthritis Care & Research
Gilbert, Arizona
Physicians East
Greenville, North Carolina
Klein and Associates MD, PA
Hagerstown, Maryland
C.V. Mehta MD Medical Corp.
Hemet, California
Pioneer Research Solutions Inc
Houston, Texas
West Tennessee Research Institute
Jackson, Tennessee
Arizona Arthritis & Rheumatology Research PLLC
Mesa, Arizona
Health Research of Oklahoma
Oklahoma City, Oklahoma
Millenium Research
Ormond Beach, Florida
Desert Medical Advances
Palm Desert, California
Springfield Clinic
Springfield, Illinois
Lovelace Scientific Resources
Venice, Florida
Poland11 sites
NZOZ Osteo-Medic s.c.
Bialystok
Centrum Medyczne Silesiana Sp. Z.o.o.
Bytom
Centrum Medyczne Pratia Katowice
Katowice
Centrum Medyczne Plejady
Krakow
NZOZ "DOBRY LEKARZ" Specjalistyczne Poradnie Lekarskie
Krakow
Specjalistyczne Centrum Medyczne Nowomed
Krakow
NZOZ Przychodnia Lekarska "Eskulap"
Skierniewice
Powiatowy Zaklad Opieki Zdrowotnej w Starachowicach
Starachowice
NZOZ "Nasz Lekarz" Pratyka Grupowa Lekarzy Rodzinnychz
Torun
AMED Medical Center
Warsaw
Rheumatica Sp. Z.o.o.
Warsaw
Argentina8 sites
Atencion Integral en Reumatologa
Buenos Aires
CER Intituto Medico
Buenos Aires
Organizacion Medica de Investigaciones (OMI)
Buenos Aires
Instituto Reumatologico Strusberg
Córdoba
CIMeL Centro dee Investigacion Medico Lanus
Lanus
Instituto CAICI
Rosario
Instituto de Asistencia Reumatologia Integral - IARI
San Fernando
Centro Médico Privado de Reumatologia
San Miguel de Tucumán
Russia8 sites
First Moscow State Medical University n.a. I.M. Sechenova of the Ministry of Health
Moscow
Scientific Research Institute of Rheumatology
Moscow
City Clinical Hospital #5
Nizhny Novgorod
GBOU VPO Orenburg State Medical University
Orenburg
Ryazan State Medical University
Ryazan
City Hospital #26
Saint Petersburg
Regional Clinical Hospital
Saratov
Vladimir Regional State Instituion of Healthcare
Vladimir
Colombia7 sites
Circaribe S.A.S
Barranquilla
Centro de Investigacion en Reumatologia y Especialidades Medicas (CIREEM)
Bogotá, 110221
Riesgo De Fractura Cayre Ips7
Bogotá, 110221
Idearg Sas
Bogotá
Medicity S.A.S.
Bucaramanga, Santander Department
Preventive Care SAS
Cundinamarca
Hospital Pablo Tobon Uribe
Medellín
Mexico7 sites
Centro de Estudios de Investigacion Basica y Clinica, SC
Guadalajara
Arke Estudios Clinicos S.A. de C.V.
México
Clinstile, S.A. de C.V.
México
Hospital General de México
México
Centro Medico Dalinde
Mexico City
Hospital Universitario José E. Gonzalez
Monterrey
OSMO
Oaxaca City
Ukraine7 sites
Communal Institution of Healthcare - Kharkiv City Clinical Hospital #13
Kharkiv
Kharkiv Medical Academy of Postgraduate Education, Department of Cardiology
Kharkiv
L.T. Malaya Therapy Institute of National Academy of Medical Sciences of Ukraine
Kharkiv
Kherson City Clinical Hospital N. A. Afanasii and Olga Tropin
Kherson
Municipal Non-Profit Institution Consultative and Diagnostic Centre of Desnyasky District of Kyiv
Kiev
Municipal Non-profit Enterprise Consultative and Diagnostic Center of Pechersk District of Kiev city
Kyiv
Vinnitsya Regional Clinical Hospital Named after M.I.Pirogov, Rheumatology Department
Vinnytsia
Guatemala6 sites
Centro Clinico
Guatemala City
Clinica de Especialidades Medicas
Guatemala City
Clinica Medica Especializada en Reumatologia
Guatemala City
Clinica Medica
Guatemala City
Reuma S.A.
Guatemala City
Reuma-Centro
Guatemala City
Bulgaria5 sites
University "Multiprofile Hospital for Active Treatment - Kaspela" LTD
Plovdiv
Multiprofile Hospital for Active Treatment - Ruse
Rousse
Diagnostic Consultative Center "Sveta Anna" LTD
Sofia
National Multiprofile Transport Hospital "Tsar Boris III," Sofia, Clinical of Internal Diseases
Sofia
University Multiprofile Hospital for Active Treatment "SV. Ivan Rilski" EAD, Sofia, Rheumatology Clinic
Sofia
Chile5 sites
Hospital Regional "Guillermo Grant Benavente"
Santiago
Prosalud
Santiago
Someal SA
Santiago
Centro de Investigacion Clinica del Sur
Temuco
Consulta Privada Dra. Ponce
Temuco
Hungary5 sites
Gyogyszervizs galo Kozpont Kft
Balatonfüred
QualiClinic Kft.
Budapest
Reumatologiai Kft.
Budapest
Markhot Ferenc Hospital, Rheumatology
Eger
Csolnoky Ferenc Hospital, Rheumatology
Veszprém
Latvia5 sites
Ltd M&M Centr
Adazi
SIA Arijas Ancane's Family Doctor
Baldone
Daugavpils Regional Hospital
Daugavpils
L. Atikes doktorats
Liepāja
'Bruninieku' polyclinic
Riga
Czechia4 sites
Revmatologie S.R.O
Brno
Revmatologicka a interni ambulance
Kladno
Revmatologicka ambulance
Praha-Nusle
PV-Medical S.R.O.
Zlín
Australia3 sites
Flinders Medical Centre
Bedford Park, Flinders Drive, South Australia
Monash Medical Centre
Clayton, Victoria
Princess Alexandra Hospital
Woolloongabba
Spain3 sites
Complejo Hospitalario Universitario A Coruña (CHUAC)
A Coruña
Sanatorio Nuestra Señora de la Esperanza
A Coruña
Hospital Parc Tauli
Sabadell
Germany2 sites
Schlossparkklinik - Akad. Lehrkrankenhaus Charite
Berlin
MVZ Rheumatologie and Autoimmun Medizin HH GmbH
Hamburg
New Zealand2 sites
Waikato Hospital
Hamilton
Timaru Rheumatology Studies
Timaru
Romania2 sites
Spitalul Clinic Sfanta Maria
Bucharest
Spitalul Clinic Judetean de Urgenta Sf. Apostol Andrei Galati
Galati
About this study
Official title: A Multicenter, Open-label, Long-term Follow-up Safety and Efficacy Study of GLPG0634 Treatment in Subjects With Moderately to Severely Active Rheumatoid Arthritis
The primary objective of the study was to evaluate the long-term safety and tolerability of filgotinib (formerly GLPG0634) for the treatment of rheumatoid arthritis.
Participants were enrolled in this open-label long-term follow-up study after they had completed one of the two core studies, GLPG0634-CL-203 (DARWIN1) (NCT01888874) or GLPG0634-CL-204 (DARWIN2) (NCT01894516), and were evaluated for any side effects that might have occured (long-term safety and tolerability) when taking filgotinib. During the course of the study, participants were also examined for long-term effects of filgotinib administration on disease activity (efficacy), participant's disability, fatigue, and quality of life.
- Conditions
- Rheumatoid Arthritis
- Being tested
- Filgotinib
- Keywords
- Methotrexate, insufficient responders
- Medical subject headings
- Arthritis, Rheumatoid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FilgotinibDrug
Also called GS-6034, GLPG0634
Administered as Oral Tablets
| Study group | Role | What they receive |
|---|---|---|
| Filgotinib Darwin 1 | Experimental | Participants in Study GLPG0634-CL-203 (NCT01888874) were rolled-over to receive an oral dose of filgotinib at a daily dose of 200 milligrams (mg) in this extension study, with the exception of male participants in the United States (US) who were limited to a daily dose of 100 mg due to a Food and Drug Administration (FDA) requirement based on a non-clinical finding. Treatment was administered until marketing, local (if applicable) regulatory and/or pertinent local reimbursement approval.
In case of intolerance or for safety reasons, and as per investigator's discretion, a daily dose of filgotinib 200 mg could be decreased to 100 mg per day, and later returned to 200 mg per day after the reasons for decreasing the dose were resolved. Receives: Drug: Filgotinib |
| Filgotinib Darwin 2 | Experimental | Participants from Study GLPG0634-CL-204 (NCT01894516) were rolled-over to receive oral dose of filgotinib tablet at 200 mg once daily (q.d) in this extension study. Treatment was administered until marketing, local (if applicable) regulatory and/or pertinent local reimbursement approval.
Participants started the study with the same dose level (filgotinib 200 mg per day) and in case of intolerance or safety reasons and as per investigator's discretion, the daily dose of filgotinib was decreased to 100 mg q.d and was returned to 200 mg per day after the reasons for decreasing the dose had resolved and at the investigator's discretion. Receives: Drug: Filgotinib |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants Experiencing Treatment-Emergent Adverse Events
An Adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.
Treatment-emergent adverse events (TEAEs) were defined as any AEs with an onset date on or after the filgotinib start date in the core studies or GLPG0634-CL-205 (NCT02065700), and no later than 30 days after permanent discontinuation of filgotinib in GLPG0634-CL-205 (NCT02065700) or of either 30 days after the last dose date.
Measured: From First dose to Week 437
Secondary outcomes (16)
Percentage of Participants Achieving American College of Rheumatology (ACR) 20 Response: Non-Responder Imputation (NRI)
The American College of Rheumatology (ACR) response was a measurement of improvement in multiple disease assessment criteria.
The ACR20 response was defined as: 1) ≥ 20% improvement from baseline in swollen joint count 66 (SJC66), and 2) ≥ 20% improvement from baseline in tender joint count 68 (TJC68), and 3) ≥ 20% improvement from baseline in at least 3 of the following 5 items: 1. Pain visual analog scale (VAS) (taken from the Health Assessment Questionnaire - Disability Index [HAQ-DI]), 2.Subject's Global Assessment of Disease Activity (SGA) (VAS), 3. Physician's Global Assessment of Disease Activity (PGA) (VAS), 4. Total HAQ-DI score, and 5. High-Sensitivity C- Reactive Protein (hsCRP).
Measured: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Percentage of Participants Achieving ACR20 Response: Observed Case (OC)
The ACR response was a measurement of improvement in multiple disease assessment criteria.
The ACR20 response was defined as: 1) ≥ 20% improvement from baseline in SJC66, and 2) ≥ 20% improvement from baseline in tender TJC68, and 3) ≥ 20% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2.SGA (VAS), 3. PGA (VAS), 4. Total HAQ-DI score, and 5. hsCRP.
Measured: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Percentage of Participants Achieving ACR50 Response: NRI
The ACR response was a measurement of improvement in multiple disease assessment criteria.
ACR50 response was defined as: 1) ≥ 50% improvement from baseline in SJC66, and 2) ≥ 50% improvement from baseline in TJC68, and 3) ≥ 50% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI) 2.SGA (VAS) 3. PGA (VAS) 4. Total HAQ-DI score 5. hsCRP.
Measured: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Percentage of Participants Achieving ACR50 Response: OC
The ACR response was a measurement of improvement in multiple disease assessment criteria.
ACR50 response was defined as: 1) ≥ 50% improvement from baseline in SJC66, and 2) ≥ 50% improvement from baseline in TJC68, and 3) ≥ 50% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI) 2.SGA (VAS) 3. PGA (VAS) 4. Total HAQ-DI score 5. hsCRP.
Measured: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Percentage of Participants Achieving ACR70 Response: NRI
The ACR response was a measurement of improvement in multiple disease assessment criteria.
ACR70 response was defined as : 1) ≥ 70% improvement from baseline in SJC66, and 2) ≥ 70% improvement from baseline in TJC68, and 3) ≥ 70% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2.SGA (VAS), 3. PGA (VAS), 4. Total HAQ-DI score, and 5. hsCRP.
Measured: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Percentage of Participants Achieving ACR70 Response: OC
The ACR response was a measurement of improvement in multiple disease assessment criteria.
ACR70 response was defined as : 1) ≥ 70% improvement from baseline in SJC66, and 2) ≥ 70% improvement from baseline in TJC68, and 3) ≥ 70% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2.SGA (VAS), 3. PGA (VAS), 4. Total HAQ-DI score, and 5.hsCRP.
Measured: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
ACR N% Improvement (ACR-N) Response: OC
ACR-N was defined as the smallest percentage improvement from core baseline in SJC66, TJC68 and the median of the following 5 items (Pain VAS [taken from the HAQ-DI], 2.SGA (VAS), 3. PGA (VAS), 4. Total HAQ-DI score, and 5. hsCRP). It had a range between 0 and 100%.
Measured: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Change From Core Baseline in Disease Activity Score Based on 28 Joints Using C-reactive Protein (DAS28[CRP]): OC
The DAS28(CRP) was a measure of the participant's disease activity calculated using the TJC (28 joints), SJC (28 joints), SGA [using a VAS on a scale of 0 (very well) to 100 (very poor)] and hsCRP using the formula:
DAS28(CRP) = 0.56 * Square root [SQRT] (TJC28) + 0.28 * SQRT(SJC28) + 0.36 * Ln(CRP+1) + 0.014 * SGA + 0.96
and the total possible score ranged from 1 to 9.4. Higher values indicated higher disease activity. A negative change from baseline indicated improvement.
Measured: Core Baseline, Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Change From Core Baseline in Simple Disease Activity Index (SDAI): OC
SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA (0 to 10 cm), PGA (0 to 10 cm), CRP (mg/dL). SDAI = TJC + SJC + SGA + PGA+ CRP. The SDAI score ranged from 0 to approximately 86. Higher SDAI indicated greater disease activity. A negative change from baseline indicated improvement.
Measured: Core Baseline, Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Change From Core Baseline in Clinical Disease Activity Index (CDAI): OC
The CDAI was the SDAI modified that excluded CRP and consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA (0 to 10 cm), PGA (0 to 10 cm). SDAI = TJC + SJC + SGA+ PGA. The CDAI score ranged from 0 to approximately 76. Higher CDAI indicated greater disease activity. A negative change from baseline indicated improvement.
Measured: Core Baseline, Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Percentage of Participants Achieving European League Against Rheumatism (EULAR) Response: OC
DAS28(CRP) was categorized into EULAR response categories (none, moderate, good) as follows:
None= Actual DAS28(CRP) ≤ 3.2, > 3.2 to ≤ 5.1, or > 5.1 AND Improvement in DAS28(CRP) from baseline ≤ 6.0 or > 0.6 to ≤ 1.2;
Moderate= Actual DAS28(CRP) ≤ 3.2 AND Improvement in DAS28(CRP) from baseline > 0.6 to ≤ 1.2, Actual DAS28(CRP) > 3.2 to ≤ 5.1 or > 5.1 AND Improvement in DAS28(CRP) from baseline > 1.2, or Actual DAS28(CRP) > 3.2 to ≤ 5.1 AND Improvement in DAS28(CRP) from baseline > 0.6 to ≤ 1.2;
Good= Actual DAS28(CRP) ≤ 3.2 AND Improvement in DAS28(CRP) from baseline > 1.2.
Measured: Core Baseline, Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Percentage of Participants Achieving ACR/EULAR Remission: NRI
A participant's disease activity status was defined as being in remission when scores on the TJC28, SJC28, CRP (actual value in mg/dL) and SGA (cm) were all ≤ 1.
Measured: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Percentage of Participants Achieving ACR/EULAR Remission: OC
A participant's disease activity status was defined as being in remission when scores on the TJC28, SJC28, CRP (actual value in mg/dL) and SGA (cm) were all ≤ 1.
Measured: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Change From Core Baseline in Physical Component Score (PCS) of Quality of Life Using the Short Form-36 (SF-36) Scores: OC
The health-related quality of life of the subject was assessed using the SF-36 with a 4-week recall period. This consists of 36 questions belonging to 8 domains in 2 components:
- Physical well-being: 4 domains: physical functioning (10 items), role physical (4 items), bodily pain (2 items), and general health (GH) perceptions (5 items).
- Mental well-being: 4 domains: vitality (4 items), social functioning (2 items), role emotional (3 items), and mental health (5 items).
These scales were from 0 to 100 with higher scores indicating a better quality of life.
Measured: Core Baseline, Extension Baseline, Weeks 48, 96, 144, 192, 240, 288, 336, 384
Change From Core Baseline in MCS of Quality of Life Using the SF-36 Scores: OC
The health-related quality of life of the subject was assessed using the SF-36 with a 4-week recall period. This consists of 36 questions belonging to 8 domains in 2 components:
- Physical well-being: 4 domains: physical functioning (10 items), role physical (4 items), bodily pain (2 items), and general health (GH) perceptions (5 items).
- Mental well-being: 4 domains: vitality (4 items), social functioning (2 items), role emotional (3 items), and mental health (5 items).
These scales were from 0 to 100 with higher scores indicating a better quality of life.
Measured: Core Baseline, Extension Baseline, Weeks 48, 96, 144, 192, 240, 288, 336, 384
Change From Core Baseline in Quality of Life Using Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale: OC
FACIT-Fatigue scale was a 13-item questionnaire, each scored on a 5-point scale: 0 (Not at all) to 4 (Very much). Negatively stated items were reversed by subtracting the response from "4" before being added to obtain a total score. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score), with a higher score indicating less fatigue. A positive change from baseline indicated better quality of life.
Measured: Core Baseline, Extension Baseline, Weeks 48, 96, 144, 192, 240, 288, 336, 384
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Feb 2014 (estimated)
- Study start25 Feb 2014
- Primary completion19 Jan 2023
- Study completion19 Jan 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (8)Papers the sponsor has linked to this study.
- Other trials for Rheumatoid ArthritisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 739 participants (actual)
Sponsor and investigators
- Lead sponsor
- Lakefront Biotherapeutics NV
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Gilead Sciences
- Responsible party
- Sponsor
- Investigators
- Galapagos Study Director, Study director, Lakefront Biotherapeutics NV
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02065700
- Sponsor's protocol ID
- GLPG0634-CL-205
- Other IDs
- 2012-003655-11
- Acronym
- DARWIN3
- Status last verified
- May 2024
- First submitted
- 14 Feb 2014
- Last updated
- 4 Jun 2024
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Qualified external researchers may request IPD for clinical trials that support an approved indication in the EU and the US for which Galapagos is the Marketing Authorisation / New Drug Application Holder, with a marketing authorisation date on or after January 1, 2021 and for which the summary results have been published on ClinicalTrials.gov (CT.gov) and/or the EU Clinical Trials Register (EU CTR). For clinical trials of newly approved compounds or indications the IPD can be requested at earliest 6 months after the EMA and FDA approval. The study last patient last visit (LPLV) must have occurred at least 18 months prior to the request.
Publications
Genovese MC, Kavanaugh A, Winthrop K, et al. Long Term Safety of Filgotinib in the Treatment of Rheumatoid Arthritis: Week 84 Data from a Phase 2b Open-Label Extension Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10).
Kavanaugh A, Westhovens R, Winthrop K, et al. Rheumatoid Arthritis Treatment with Filgotinib: Week 156 Safety and Efficacy Data from a Phase 2b Open-Label Extension Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10).
R. Westhovens, R. Alten, K. Winthrop, et al. Long term safety of filgotinib in the treatment of rheumatoid arthritis: week 108 data from a phase 2b open-label extension study. [abstract]. Ann Rheum Dis. 2018;77 (suppl 2)
Kavanaugh A, Genovese MC, Winthrop K, et al. Rheumatoid Arthritis Treatment with Filgotinib: Week 132 Safety Data from a Phase 2b Open-Label Extension Study [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9).
Kavanaugh A, Westhovens RR, Winthrop KL, Lee SJ, Tan Y, An D, Ye L, Sundy JS, Besuyen R, Meuleners L, Stanislavchuk M, Spindler AJ, Greenwald M, Alten R, Genovese MC. Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs. J Rheumatol. 2021 Aug;48(8):1230-1238. doi: 10.3899/jrheum.201183. Epub 2021 Feb 1.
PubMed 33526618Westhovens R, Winthrop KL, Kavanaugh A, Greenwald M, Dagna L, Cseuz R, Besuyen R, de Vries D, Modgill V, Le LH, Genovese MC, Emery P, Verschueren P, Alten R. Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study. RMD Open. 2025 Jan 30;11(1):e004857. doi: 10.1136/rmdopen-2024-004857.
PubMed 39884731Balsa A, Wassenberg S, Tanaka Y, Tournadre A, Orzechowski HD, Rajendran V, Lendl U, Stiers PJ, Watson C, Caporali R, Galloway J, Verschueren P. Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis. Rheumatol Ther. 2023 Dec;10(6):1555-1574. doi: 10.1007/s40744-023-00599-1. Epub 2023 Sep 25.
PubMed 37747626Combe B, Besuyen R, Gomez-Centeno A, Matsubara T, Sancho Jimenez JJ, Yin Z, Buch MH. Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis. Rheumatol Ther. 2023 Feb;10(1):35-51. doi: 10.1007/s40744-022-00494-1. Epub 2022 Oct 7.
PubMed 36205910